Chinese Clinical Oncology

Effects of nuclear factor 90 knockdown on proliferation of hepatocellular carcinoma cells and its mechanism

SONG Dan， WEI Li， WU Jiaxue.

Chinese Clinical Oncology. 2017, 22 (5): 385.

Abstract ( 463 )

PDF（pc） (1696KB) ( 465 )

Save

Objective To investigate the effect of nuclear factor 90 （NF90） knockdown on proliferation of hepatocellular carcinoma （HCC） cell and explore its mechanism. Methods The oligonucleotides targeting NF90 were cloned into the PLKO plasmid and packaged with lentiviral shRNA to knockdown NF90 （with green fluorescent labels and G418 resistance）. The hepatocellular carcinoma cells QGY-7703 and SMMC-7721 were divided into control group and intervention group. The virus containing random sequence shRNA and targeting NF90 shRNA were infected， respectively. After 48 h， positive cells were stained with green fluorescence， and the positive monoclonal cell lines were screened by G418. The expression level of NF90 protein was identified by Western blotting. Finally， a cell line named shRNA-ns was selected in the control group. Two cell lines of NF90 knockdown named shRNA-1 and shRNA-2. Cell growth activity was detected by CCK-8 and clone formation analysis. The relationship between NF90 and PARP1 was detected by fluorescence localization assay. Results The expression of NF90 in shRNA-1 and shRNA-2 cells was significantly lower than that in shRNA-ns cells， indicating that the knockdown of NF90 by lentivirus was effective. Compared with shRNA-ns cells， shRNA-1 and shRNA-2 cells were slow to grow and the number of clones was decreased with statistically significant difference （P＜0.01）. NF90 and PARP1 bind to each other in the cell and co-localize in the nucleus. Conclusion NF90 knockdown inhibits HCC cell proliferation， and NF90 may affect HCC cell proliferation by interacting with PARP1.

Related Articles | Metrics

The effect of microRNA-133b on migration and invasion of glioblastoma

ZHANG Dongzhi， CHANG Liang， SU Jun， WANG Chao， TAN Chunlei， LI Guofu， ZHANG Xuexin.

Chinese Clinical Oncology. 2017, 22 (5): 391.

Abstract ( 484 )

PDF（pc） (1120KB) ( 410 )

Save

Objective To investigate the effect of microRNA-133b （miR-133b） on glioblastoma （GBM） cell and to analyze its possible molecular mechanism. Methods Reverse transcription-polymerase chain reaction（RT-PCR） was used to detect the expression of miR-133b in 20 human GBM samples and normal human glial cells HBE. Transwell migration and invasion assays were used to evaluate the effects of miR-133b on cell migration and invasion. Western blotting and a luciferase reporter assay were used to identify the target genes of miR-133b. Results Compared with the HBE， miR-133b was significantly increased in GBM tissues （1.0±0.17 vs. 2.42±0.69, P＜0.05）； In Transwell invasion and migration experiments， compared to group transfected with NC， the cells transfected with miR-133b mimic could inhibit the migration and invasion （P＜0.05）； In Western blotting， compared to cells that transfected with NC， the cells transfected with miR-133b mimic had a lower expression of MMP-14 protein （P＜0.05）. Furthermore， MMP-14 was identified as a direct target gene of the miR-133b by luciferase reporter gene analysis. Conclusion miR-133b can inhibit the migration and invasion of GBM by direct targeting MMP-14, and it can be used as a candidate target for diagnosis and treatment of GBM.

Related Articles | Metrics

Detection of K-Ras mutation in exosomes instead of tumor tissues from patients with colorectal cancer

CUI Cong， JIN Yang， TAN Zhaoli， WANG Yan， WANG Youliang， XU Jianming.

Chinese Clinical Oncology. 2017, 22 (5): 395.

Abstract ( 489 )

PDF（pc） (981KB) ( 362 )

Save

Objective To investigate the value of the 12th codon of K-Ras gene mutation detection in the serum exosomes instead of the tumor tissues in patients with colorectal cancer. Methods The peripheral blood samples of 90 patients pathologically diagnosed as locally advanced or metastatic colorectal cancer from May 2014 to September 2015 in our hospital were collected. The serum exosomes were extracted by ExoQuick agent. Exosomes and blood cells were extracted by salting out method. The 12th codon of K-Ras gene was amplified by PCR， and the mutation was detected by next generation sequencing. The specificity of serum exosomes DNA and blood cell DNA mutations was compared. Mutations of 12th codon of K-Ras gene were compared between exosomes and histological detection. Results Among 90 cases with colorectal cancer， 43 cases of the 12th codon mutation in K-Ras gene were detected with the mutation rate of 47.8％. Four kinds of mutation were detected， and the G12D mutation rate was the highest. Compared with histological examination， the sensitivity was 90.6％ and the consistency was 81.1％（Kappa=0.62，P＜0.05）. Conclusion The consistent of serum exosome DNA used for detection of tumor-related mutation was higher than that of tumor tissues， which can be used as a source of liquid biopsy to guide the individualized treatment of tumors.

Related Articles | Metrics

Effects of co-stimulating molecule B7-H3 expression on metastasis of hepatocellular carcinoma

KANG Fubiao，WANG Ling，ZHANG Yinge，WANG Yuwen， SUN Dianxing.

Chinese Clinical Oncology. 2017, 22 (5): 400.

Abstract ( 442 )

PDF（pc） (2381KB) ( 299 )

Save

Objective To investigate the effects and the mechanism of co-stimulatory molecule B7-H3 on tumor metastasis of hepatocellular carcinoma （HCC）. Methods The B7-H3 expressions of surgically resected specimens in 37 pairs of HCC patients including 37 metastatic HCC cases and 37 cases without metastasis were confirmed by immunohistochemistry. The shRNA silencing plasmid was designed and transfected into HepG2 cells to down-graduate B7-H3 gene expression. The mRNA and protein expressions of EMT-related molecules including E-cadherin， vimentin and N-cadherin were detected by RT-PCR and Western blotting， separately. Results The expression of B7-H3 in tumor margin and metastases was higher than that of internal primary lesions. The B7-H3 expressions of primary lesions in the group with metastasis were much higher than which in the group without metastasis （P=0.01）. The mRNA and protein expression of E-cadherin in B7-H3 shRNA group were 1.27±0.23 and 1.03±0.27， which were higher than those of scramble shRNA group （0.71±0.16，0.80±0.05） and control group （0.63±0.11，0.71±0.09）. The difference was statistically significant （P＜0.05）. The mRNA and protein levels of vimentin in B7-H3 shRNA group were 0.31±0.14 and 0.36±0.06， which were lower than scramble shRNA group（0.79±0.09，0.81±0.15） and control group（0.82±0.04，0.98±0.15）. The difference was statistically significant （P＜0.05）. The mRNA and protein levels of N-cadherin in B7-H3 shRNA group were 0.68±0.09 and 0.56±0.16， which were lower than scramble shRNA group（1.28±0.26，0.86±0.09） and control group（1.42±0.17，1.02±0.11）.The difference was statistically significant （P＜0.05）. Conclusion Costimulatory molecule B7-H3 could promote tumor metastasis of HCC， which might be achieved by regulating the EMT mechanism.

Related Articles | Metrics

Study on the relationship between FcγRⅢa 158V／F polymorphism and the efficacy of rituximab-based regimens in the first-line treatment of diffuse large B cell lymphoma

JIN Xuan， DENG Lijuan， WANG Xiaogan， DING Ning， SONG Yuqin， ZHU Jun.

Chinese Clinical Oncology. 2017, 22 (5): 406.

Abstract ( 433 )

PDF（pc） (1011KB) ( 319 )

Save

Objective To explore the relationship between Fc gamma receptor Ⅲa 158V／F （FcγRⅢa 158V／F） polymorphism and clinical response to standard frontline treatment with rituximab （RTX）-based regimens in Chinese diffuse large B-cell lymphoma （DLBCL） patients. Methods Nested PCR combined with sanger sequencing were used to detected FcγRⅢa 158V／F genotypes in 265 DLBCL patients. All patients receiving 6 （1-8） cycles of R-CHOP （rituximab， cyclophosphamide， doxorubicin， vincristine and prednisone） as frontline therapy were assessable for the efficacy. The relationship between FcγRⅢa 158V／F polymorphism and the efficacy and prognosis of patients was analyzed. Results Among 265 patients， 27 （10.2％） patients with V／V genotype， 107 （40.4％） with V／F and 131 （49.4％）with F／F were identified. Patients with different FcγRⅢa 158V／F genotypes did not have any difference in terms of age， molecular subtypes， lactate dehydrogenase （LDH） or international prognostic index （IPI）; However, it only related to gender（P＜0.05）. The overall response rate （RR） was 85.2％, 84.1％ and 83.2％ in V／V， V／F and F／F， respectively. There was no significant difference between the treatment responses of the three groups （P＞0.05）. With a median follow-up of 60.7 months（range： 0.8-109.5）， 103（38.9％）patients relapsed or progressed， and 77（29.1％） died. There was no difference between homozygous F／F and V allele carriers as for the 5-year progression-free survival rate （61.1％ vs. 62.4％， P=0.757） and 5-year overall survival rate （69.2％ vs. 74.2％， P=0.278）. But in the subgroup of early stage （Ⅰ-Ⅱ）， patients with V allele carriers were found to have a higher 5-year overall survival rate than that in homozygous F （94.7％ vs.77.3％， P=0.003）. The 5-year progression-free survival rates for F／F genotype and V／V+V／F genotype were 85.9％ and 75.9％（P＞0.05）. As for Ⅲ-Ⅳ stage， there was no significant difference in progression-free survival rate and overall-survival rate between patients with different FcγRⅢa 158V／F genotypes （P＞0.05）. Conclusion FcγRⅢa 158V／F polymorphisms could not predict response to RTX-based regimes as frontline therapy for DLBCL patients， but in the subgroup of early stage， this polymorphism may be a biomarker to predict response.

Related Articles | Metrics

Expression of EphB3 in ovarian serous carcinoma and its clinical significance

SUN Yuejun，XU Hongming，SHEN Qinzhi，CHEN Wei.

Chinese Clinical Oncology. 2017, 22 (5): 412.

Abstract ( 244 )

PDF（pc） (1827KB) ( 284 )

Save

Objective To explore the expression of receptor tyrosine kinase EphB3 in normal fallopian tube， ovarian serous benign tumor and ovarian serous carcinoma， and its relation to clinical pathological parameters of ovarian serous carcinoma. Methods Nine cases of normal fallopian tubes， 12 cases of benign tumors and 53 cases of ovarian serous carcinomas were collected. All tissues were buffered formalin fixed and paraffin embedded. EnVision immunohistochemistry was used to detect the expression of EphB3. The relationship between expression of EphB3 and clinical pathological parameters was analyzed. Results EphB3 was highly expressed in normal fallopian tube （100.0％） and benign tumor （75.0％） and reduced expression in ovarian serous carcinoma （18.9％） with statistical difference（P＜0.001）. Expression of EphB3 was negatively associated with tumor grade（r=-0.606， P＜0.001）and FIGO stage （r=-0.463， P＜0.001）， and was not related to age， metastasis of greater omentum， metastasis of peritoneal cavity and lymph node metastasis of pelvic cavity. Conclusion EphB3 may be used to distinguish low and high grade tumor， and benefit for diagnosis and therapy of ovarian carcinoma.

Related Articles | Metrics

Associations of family history of gastric cancer with clinicopathologic characteristics and prognosis of gastric cancer

LI Dan， WANG Deqiang， WANG Hongyu， REN Jin， CHEN Deyu， GU Hangang， CHEN Wenqi， LI Xiaoqin.

Chinese Clinical Oncology. 2017, 22 (5): 417.

Abstract ( 284 )

PDF（pc） (1044KB) ( 304 )

Save

Objective To investigate the differences of clinicopathologic characteristics and prognoses of gastric cancer between patients with or without family history of gastric cancer. Methods A retrospective study was conducted in 456 gastric cancer patients from 2011 to 2015， and among them 102 cases were with family history of gastric cancer. A two-sided χ2 was used to test the difference of clinicopathologic characteristics between patients with or without family history of gastric cancer. Survival curves were calculated by Kaplan-Meier method with Log-rank test. Both univariate and multivariate Cox regression models were used to analyze risk factors that impact overall survival （OS）. Results In patients with family history of gastric cancer， the proportions of patients with onset age ≥50 years， the longest diameter of tumor ＜5 cm， histological grade of Ⅰ-Ⅱ and M0 stage were significantly higher than that in patients without family history of gastric cancer （P＜0.05）. The median OS of patients with family history of gastric cancer was 56.1 months， longer than 51.0 months of those without family history of gastric cancer， but without statistic significance （P=0.318）. However， in the subgroup of onset age ≥50 years， patients with family history of gastric cancer had OS superiority than those without family history of gastric cancer （unachieved vs. 53.0 months， P=0.021）. Furthermore， Cox regression models analysis showed that N stage and M stage were independent factors influencing OS in patients with family history of gastric cancer， and the longest diameter of tumor， tumors location and M stage were independent factors influencing OS in those without family history of gastric cancer. Conclusion Gastric cancer patients with or without family history of gastric cancer have different clinicopathologic characteristics， and OS between those patients may have certain difference.

Related Articles | Metrics

The influence of early enteral nutrition or parenteral nutrition therapy on the immune function and nutritional status of gastric cancer patients with radical surgery

WANG Dan， ZHANG Lili， CHENG Xiaona， ZHANG Weiguo.

Chinese Clinical Oncology. 2017, 22 (5): 423.

Abstract ( 260 )

PDF（pc） (880KB) ( 263 )

Save

Objective To investigate the effect of early enteral nutrition or parenteral nutrition on immune function and nutritional status in patients after radical gastrectomy for gastric cancer. Methods A total of 120 patients with gastric cancer treated in our hospital from January 2013 to December 2015 were selected and divided into experimental group and control group according to random number table method. The control group was treated with parenteral nutrition， and the experimental group was given early enteral nutrition support. The immune function and nutritional status of the two groups were compared. Results On the first day after operation， the activity of the immune cells in the two groups was weaker than that before operation （P＜0.05），including CD3+， CD4+， CD4+／CD8+ and NK. On the seventh day after operation， the activity of the immune cells in the experimental group was similar to the preoperative level （P＞0.05）. The activity of the immune cells in control group was significantly lower than those of the preoperative level and the experimental group （P＜0.05）. The fever time， recovery time of intestinal function， exhaust time and hospitalization time in the experimental group were significantly shorter than those of the control group （P＜0.05）. On the first day after operation， the contents of albumin and prealbumin in two groups were（25.2±5.8）g／L, （136.7±18.8）g／L and （25.5±6.0）g／L, （134.3±17.7）g／L， which were lower than those of two groups before operation. On the seventh day after operation， the contents of prealbumin and albumin in experimental group were （172.5±22.8） g／L and （37.6±7.7） g／L， which were significantly higher than those of control group （P＜0.05）. The complication rate of the experimental group was 11.7％， which was significantly lower than that of control group （28.3％），and the difference was statistically significant（P＜0.05）. Conclusion Early enteral nutrition therapy can effectively improve the nutritional status and immune function of patients with gastric cancer. It is worth to be popularized in clinical use.

Related Articles | Metrics

Efficacy and toxicity of trastuzumab plus endocrine therapy as maintenance therapy hormone receptor- and HER-2-positive metastatic breast cancer

ZHANG Yanqiu， SUN Lizhu， WANG Yifan， WANG Jian， YIN Yongmei.

Chinese Clinical Oncology. 2017, 22 (5): 427.

Abstract ( 313 )

PDF（pc） (916KB) ( 293 )

Save

Objective To evaluate the efficacy and toxicity of trastuzumab plus endocrine therapy as maintenance therapy after first-line chemotherapy plus trastuzumab for HR-positive and HER-2-positive metastatic breast cancer. Methods Patients with HR+／HER-2+ metastatic breast cancer receiving first-line chemotherapy and trastuzumab and sequentially continued endocrine therapy with ongoing trastuzumab as maintenance therapy were enrolled in this study. The clinical data was retrospeetively collected and efficacy and toxicity of the maintenance trastuzumab and endocrine therapy was analyzed. Response to maintenance therapy was assessed by RECIST criteria 1.1 and toxicity was evaluated according to Common Terminology Criteria for Adverse Events （CTCAE） v4.0. The prognosis was analyzed according to the follow-up data. Results Thirty-one patients were enrolled. The median progression-free survival of maintenance therapy was 12.0 months （95％CI： 5.4-18.6 months）. The maintenance regimen achieved response rate of 26.9％ and disease control rate of 88.5％. The most common adverse events were mild， including fatigue （19.4％）， hot flashes （16.1％） and nausea and vomiting （9.7％）. Conclusion Adding maintenance endocrine therapy to ongoing trastuzumab upon the completion of first-line chemotherapy plus trastuzumab might improve clinical outcomes for HR+／HER-2+ metastatic breast cancer， and the regimen was well tolerated.

Related Articles | Metrics

Clinical characteristics of lung adenocarcinoma bearing acquired resistance of EGFR-TKI

ZHANG Ping，WU Xiaonan，NIE Xin，AI Bin，LI Lin，CHENG Gang.

Chinese Clinical Oncology. 2017, 22 (5): 432.

Abstract ( 345 )

PDF（pc） (881KB) ( 255 )

Save

Objective To investigate the clinical characteristics of acquired resistance of epidermal growth factor receptor （EGFR） sensitive mutation in patients with advanced lung adenocarcinoma treated with first-line EGFR-tyrosine kinase inhibitor（EGFR-TKI）therapy. Methods A total of 193 patients with advanced lung adenocarcinoma bearing EGFR sensitive mutation were enrolled from January 2011 to December 2015， and 120 patients of them were given the first-line EGFR-TKI therapy. The relationship of short-term efficacy， as well as EGFR mutation types and locations of tumor progression was analyzed. Results No complete remission （CR） was observed in 120 patients receiving the first-line EGFR-TKI treatment. Eighty patients （66.7％） achieved partial remission （PR） and the median progression-free survival （PFS） was 12.1 months. Thirty-six patients （30.0％） achieved stable disease （SD） and the median PFS was 6.1 months. The difference of PFS between them had statistical significance （P＜0.05）. Among patients achieved PR and SD， the exon 19 deletions was found in 64 cases （55.2％） and the median PFS was 11.0 months. The mutation of L858R occurred in 52 cases （44.8％） and the median PFS was 8.6 months， the differences between PFS also had statistical significance （P＜0.05）. Fifty cases （43.1％） with acquired resistance only had progresses in original lesions， and 66 patients （56.9％） were found new lesion metastases. At the time of disease progression， lung progression accounted for 37.9％， followed by brain metastases accounted for 26.7％. Clincial efficacy （PR／SD） and EGFR mutation （exon 19 deletions／L858R mutations） were not related to location of tumor progression and original/new lesions（P＞0.05）. Conclusion Lung is the most common locations of tumor progression after acquired resistance to EGFR-TKI in patients with EGFR mutation， followed by brain metastases. The location of tumor progression and clinical efficacy， as well as EGFR mutation genotypes are not exactly related.

Related Articles | Metrics

Clinical observation of olanzapine in prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogetic chemotherapy

ZHOU Dong‘ai，MA Jin’an， ZHAO Yanzhong， ZHANG Haixia，LUO Danjing，HU Hao， PENG Hao， HU Chunhong.

Chinese Clinical Oncology. 2017, 22 (5): 436.

Abstract ( 281 )

PDF（pc） (908KB) ( 373 )

Save

Objective To evaluate the efficiency and safety of olanzapine in acute and delayed chemotherapy-induced nausea and vomiting （CINV） among Chinese cancer patients who received highly emetogenic chemotherapy. Methods This experiment was designed as a randomized， self-crossover and blank control clinical trial. Two sequential cycles of highly emetogenic chemotherapy were carried out on 52 cases of malignant tumor patients who met the inclusion criterion. All the patients received a sequential A／B or B／A chemotherapy cycle randomly. In cycle A （blank control group）， each patient should receive the standard anti-nausea treatment by intravenous injection 30 minutes before chemotherapy， including palonosetron （0.25 mg， d1） and dexamethasone （10 mg， d1-d3）. In chemotherapy cycle B （olanzapine group）， patients not only received standard anti-nausea treatment like cycle A， but also a additional olanzapine treatment （10 mg po, qn） from the day before chemotherapy to the fifth day after chemotherapy administration. The primary endpoint in this study was the complete control rate of the nausea and vomiting happened within 5 days after chemotherapy administration， and the second endpoint was the safety of anti-nausea treatment. Results A total of 50 patients could be evaluated who fulfilled two different cycles of chemotherapy， and another 2 patients dropped out. When compared with non-olanzapine group， olanzapine group had a higher complete control rate of acute nausea （88.0％ vs. 52.0％， P＜0.05）， delayed nausea （72.0％ vs. 20.0％， P＜0.05）， and delayed vomiting （86.0％ vs. 64.0％， P＜0.05）. However， olanzapine group and non-olanzapine group both had a high complete control rate of acute vomiting （94.0％ vs. 86.0％）， but there was no significant difference（P＞0.05）. The main adverse effects suffered by patient in this trial included dizziness， somnolence， dry mouth， fatigue， constipation and orthostatic hypotension. The proportion and degree of adverse effect in olanzapine group and non-olanzapine group were very low， and there was no significant statistical difference between two groups（P＞0.05）. Conclusion Olanzapine can further improve the control efficiency of CINV based on the standard treatment of palonosetron and dexamethasone without increasing the adverse effect of treatment.

Related Articles | Metrics

Clinicopathologic study of gyriform schwannoma

LI Hongling， MAO Rongjun，XIE Le， XU Yuanyuan.

Chinese Clinical Oncology. 2017, 22 (5): 441.

Abstract ( 267 )

PDF（pc） (2539KB) ( 262 )

Save

Objective To investigate the clinical and pathological features of gyriform schwannoma（GSW）. Methods The clinical features， performance of light microscopy， immunohistochemistry and ultrastructure of 4 cases of GSW were observed. Results There were two males and two females. Each of the 2 cases was located in the head and neck. GSW was a slowly growing painless mass or slight tenderness with clear boundary. The capsule of the tumor was integrity， with diameter of 2-4 cm， and the section was grayish yellow. The tumor tissues distributed as solid flakes， were composed of round or oval cells. The cytoplasm was rich and red， and the nuclei were arranged closely. Tumor cells were matched with each other in irregularly trabecular or branched manner. Protuberances with obvious polarity were distributed in trabecular or branched nuclei on both sides， forming gyriform appearance. Immunohistochemical method showed that there were expressions of Vimentin， S-100 protein， CD56， Bcl-2 and PGP9.5，with diffuse weakly-positive expression of CD99，and no expression of calponin， β-catenin， desmin， CD34， MSA， SMA， GFAP， collagen IV， CyclinD1， laminin， AE1／AE3 and p63. The electron microscopy observation showed that tumor cells possessed features of nerve sheath cells. Conclusion GSW has unique morphologic features and its immunophenotype and ultrastructural characteristics both possess characteristics of nerve sheath cell differentiation. Therefore， it is presumed that GSW is a new subtype of schwannoma.

Related Articles | Metrics

Clinical observation of FOLFIRI as second-line chemotherapy for advanced duodenal cancer

PAN Jun， QIN Shukui， YANG Ningrong， HAO Liping， ZHAO Xiaoyue， WANG Lin.

Chinese Clinical Oncology. 2017, 22 (5): 446.

Abstract ( 338 )

PDF（pc） (905KB) ( 270 )

Save

Objective To evaluate the efficacy and safety of FOLFIRI as second-line chemotherapy for advanced duodenal cancer. Methods Patients with advanced duodenal cancer who have failed to first-line therapy from June 2008 to January 2016 were analyzed retrospectively. Nine patients received FOLFIRI regiments as second-line chemotherapy. The efficacy and safety were evaluated by RECIST 1.1 and NCI-CTC 4.0 criteria. Overall survival （OS） and progression-free survival （PFS） were analyzed by Kaplan-Meier method. Results All patients were available for evaluating toxicity and effectiveness. The total treatment cycle was 41， and the median treatment cycle was 4（3-8 cycles）. The response rate was 11.1％ and disease control rate was 66.7％， including 1 case of PR， 5 cases of SD and 3 cases of PD. The median OS was 19.3 months and the median PFS was 6.5 months. The major treatment-related side effects including leucopenia， neutropenia， anemia， fatigue， nausea and etc， were mainly in grade 1-grade 2. Conclusion FOLFIRI is effective and tolerable in advanced duodenal cancer as second-line chemotherapy.

Related Articles | Metrics

Clinical observation on efficacy of body-γ-knife combined with chemotherapy in the alleviative treatment of supeerior vena cava syndrome

WU Qingmu，ZHANG Jiangling，ZHEN Weibin，GAO Qinglong.

Chinese Clinical Oncology. 2017, 22 (5): 450.

Abstract ( 305 )

PDF（pc） (1222KB) ( 302 )

Save

Objective To investigate the efficacy of the alleviative treatment of superior vena cava syndrome（SVCS） combined body-γ-knife with chemotherapy. Methods Fifty-five cases of SVCS were treated with γ-knife combined with 1 cycle chemotherapy in the. After the γ-knife treatment，the patients were received 4 to 6 cycles of chemotherapy；the 50％ isodose curve was used as the prescerption isodose curve to wrap PTV，and the 60％ odose curve wrapped more than 90％ GTV；according to the pathological type，the total dose was 45-54 Gy for 10-12 fractions. The symptom relief rate，short-term efficacy and long-term efficacy were observed. Results All of the 55 patients were accomplished treatment according to the plan， all the symptoms of SVCS were relieved during the treatment of γ-knife and median treatment was 6 times.There was no one patient who had not been relieved.The complete remission was achieved in 28 cases （50.9％） within two weeks，the total effective rate of two months was 98.2％（54／55）. There was no one patient with PD. All patients were followed up for 1-31 months. The 1-year survival rate was 72.7％（40／55）， 2-year survival rate was 43.6％（24／55）；4 cases of grade 0-1 grade acute radiation pneumonitis （7.2％），3 cases of grade 0-1 grade acute radiation esophagitis （5.4％），9 cases of grade 0-2 bone marrow suppression （16.3％），12 cases of grade 0-2 gastrointestinal reaction （21.8％），4 cases of alopecia （7.2％），and did not appear 3-4 grade adverse reactions. Conclusion γ-knife combined with chemotherapy in the treatment of SVCS has the characteristics of fast response，high efficiency，low recurrence rate，good tolerability and fewer side effects，therefore combined body-γ-knife with chemotherapy as therapeutic strategy is a good method to treat SVCS.

Related Articles | Metrics

Progression in molecular-targeted therapies for gastric cancer

LUO Huiqin， HE Yifu.

Chinese Clinical Oncology. 2017, 22 (5): 455.

Abstract ( 326 )

PDF（pc） (954KB) ( 636 )

Save

Incidence of gastric cancer in China is almost half of the morbidity in the world. Because the early clinical symptoms are not typical and early gastric cancer screening is not enough in China， the majority of patients diagnosed with advanced gastric cancer. Traditional chemotherapy was the mainly treatment options for advanced gastric cancer， but the curative effect of chemotherapy was still limited and reached the bottleneck. With the research development of tumor molecular biology， molecular-targeted therapy for the treatment of advanced gastric cancer has brought a new dawn and hope. This thesis summarizes the new progression in targeted therapy of gastric carcinoma in recent years， analyzes the drug efficacy and safety， and provides some references for clinical treatment.

Related Articles | Metrics

Research progress of CD20 negative diffuse large B cell lymphoma

SUN Mengqi， ZHAO Shu， ZHANG Qingyuan.

Chinese Clinical Oncology. 2017, 22 (5): 461.

Abstract ( 438 )

PDF（pc） (890KB) ( 566 )

Save

The CD20-negative diffuse large B-cell lymphoma （DLBCL） is a rare and heterogeneous group of lymphoproliferative disorders. Given the lack of CD20 expression， atypical cellular morphology and aggressive clinical behavior characterized by chemotherapy resistance and inferior survival rates， CD20-negative DLBCL represented a challenge from the diagnostic and therapeutic perspectives. This review introduces the clinical characteristics， prognosis and treatment of different types of CD20-negative DLBCL to improve clinicians' awareness for this kind of malignancy and to enhance its therapeutic effect.

Related Articles | Metrics

The feasibility of the detection of circulating tumor cells by CelltracksAutoPrep system

HAN Lu， LI Sheng， WANG Zhenping， CUI Kai.

Chinese Clinical Oncology. 2017, 22 (5): 465.

Abstract ( 330 )

PDF（pc） (905KB) ( 254 )

Save

At present， more and more research indicates that Celltracks® AutoPrep® misses circulating tumor cells （CTCs） with atypicalepithelial characteristics，which have a stronger ability of invasion and metastasis than CTCs simply expressing epithelial characteristic and a higher value to judge efficacy and prognosis. This paper reviews the contrast between Celltracks® AutoPrep® system and ISET technology， and the effect of EpCAM expression， hybrid， EMT+tumor， circulating tumor stem cells and irreversible EMT+tumor cells on the detection rate of Celltracks® AutoPrep® system， as well as the feasibility of Celltracks® AutoPrep® system for detecting CTCs.

Related Articles | Metrics

Immunological properties and immunotherapy of tumor draining lymph nodes

MENG Yaqiu， GU Jun.

Chinese Clinical Oncology. 2017, 22 (5): 469.

Abstract ( 3229 )

PDF（pc） (927KB) ( 1459 )

Save

Tumor-draining lymph node，abbreviated as TDLN， refers to the lymph node affected by tumor cells through lymphatic ducts， including various types of immune cells， like nature killer cells， T cells， antigen presenting cells and B cells. Because of the presence of these immune cells and the unique location of TDLN located downstream of the tumor， TDLN becomes an important site of anti-tumor immune response. However， TDLN， often developing immune tolerance to the tumor， becomes the transfer relay station of tumor cells to other tissues. In the immunotherapy of TDLN， except vitro-activate cell therapy and in vivo-activated cell therapy， some new treatments， such as targeted therapy， are becoming the focus of research. This article reviews the immunological properties of TDLN， and the mechanism and research progress of TDLN related immunotherapy.

Related Articles | Metrics

标准刊号：	ISSN 1009-0460
	CN 32-1577/R